UniQure's Huntington's gene therapy maintains benefit at four years, though effect size narrows
Four-year follow-up data for AMT-130 continue to show slowed disease progression compared with natural history, but the magnitude of benefit is smaller than reported at three years.
UniQure has presented four-year follow-up data for AMT-130, its investigational intrathecally delivered gene therapy for Huntington's disease, according to reporting by Stat News. The therapy, which uses an AAV5 vector to deliver a microRNA targeting huntingtin mRNA, continues to demonstrate a slowing of disease progression relative to natural-history comparators.
However, the updated analysis shows a reduced magnitude of benefit compared with the equivalent assessment reported approximately one year ago. The company has not yet published full peer-reviewed data for this timepoint; the figures reported by Stat News appear to derive from conference or investor presentations.
Huntington's disease is a monogenic, autosomal dominant neurodegenerative disorder caused by CAG-repeat expansion in the HTT gene. There are currently no disease-modifying therapies approved for it. AMT-130 remains in clinical development; no regulatory submission has been announced.
The narrowing of apparent effect size over time warrants careful interpretation. Natural-history cohort comparisons can be subject to selection bias, and longer follow-up periods introduce additional confounders. Independent peer-reviewed publication of the full dataset will be important for researchers and clinicians assessing the trajectory of benefit.
Plain-language version
For patients, families, and general readers. Educational only — not medical advice.
UniQure, a biotechnology company, has shared new information about its experimental Huntington's disease gene therapy called AMT-130. Huntington's disease is an inherited condition caused by a change in a single gene; it gradually affects movement, thinking, and behaviour. There is currently no approved treatment that slows the disease.
The new data, covering four years of follow-up, suggest the therapy continues to slow how quickly the disease progresses compared with what would be expected without treatment. However, the degree of slowing appears somewhat smaller than was reported a year ago, and the full results have not yet been published in a peer-reviewed scientific journal.
Researchers and doctors will need to study the complete data carefully before drawing firm conclusions. The therapy is still in clinical trials and is not yet approved anywhere.
This is an educational summary, not medical advice. If anything here raises questions for you, please speak with your GP or a clinical professional.
Sources
Read the original reporting — these are the public sources this summary draws from.
-
Primary source Stat News · 2026-09-29UniQure's gene therapy continues to slow Huntington's progression after four years